Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
Oncotarget. 2018 Nov 09;9(88):35809-35812
Authors: Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, Ross JS, Ali SM
Abstract
CGP results from >60,000 cases were screened to identify NTRK fusion events from cases of neuroendocrine tumors. 2417 NET patients from diverse anatomic sites were identified. From this dataset, six cases harbored NTRK fusions which included intra- and inter-chromosomal translocations. A NTRK fusion frequency of approximately 0.3% was found across all subtypes of NETs. Three cases involved translocations of NTRK1 with unique fusion partners (GPATCH4, PIP5K1A, CCDC19). Co-occurring alterations occurred in five cases. NTRK alterations were identified in nearly the full spectrum of NETs, including from the small intestine, pancreas, lung, and others. With the late stage clinical development of NTRK TKIs (including entrectinib and larotrectinib), these findings may further inform targeted approaches to therapy in NET.
PMID: 30533196 [PubMed]
from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2EemJEq
No comments:
Post a Comment